Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.59 |
| ▸ | ALPI | P09923 | 1/20 | 0.59 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.59 |
| ▸ | XIAP | P98170 | 1/20 | 0.59 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
| ▸ | SLC15A1 | P46059 | 3/20 | 0.51 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.47 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.46 |
| ▸ | SRR | Q9GZT4 | 2/20 | 0.46 |
| ▸ | CTSC | P53634 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | ANPEP | P15144 | 1/20 | 0.43 |
| ▸ | LAP3 | P28838 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4421753 | 1.00 | SLC7A5 (0.59) | SLC7A5ALPIPKMPTGS1XIAP | |
| Phenylalanine SCHEMBL15323730 | 0.90 | SLC7A5 (0.61) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL6521570 | 0.85 | SLC7A5 (0.59) | SLC7A5HDAC8 | |
| SCHEMBL20873690 | 0.85 | ALPI (0.58) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL6593251 | 0.85 | ALPI (0.58) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL6586336 | 0.85 | ALPI (0.58) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL28148514 | 0.85 | SLC7A5 (0.59) | SLC7A5HDAC8 | |
| SCHEMBL2785098 | 0.83 | SLC7A5 (0.70) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL28291992 | 0.82 | SLC7A5 (0.63) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL288607 | 0.82 | SLC7A5 (0.68) | SLC7A5ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 337 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6617127-B2 | Using N-formylaspartylphenylalanine compound | HOLLAND SWEETENER COMPANY, V.O.F. (NL) | 2003-09-09 | — | — | US | claimed |
| EP-1140982-B1 | SYNTHESIS AND RECOVERY OF ASPARTAME INVOLVING ENZYMATIC DEFORMYLATION STEP | HOLLAND SWEETENER CO (NL) | 2003-04-23 | — | — | EP | claimed |
| US-20020025549-A1 | Synthesis and recovery of aspartame involving enzymatic deformylation step | DSM IP ASSETS BV (NL) | 2002-02-28 | — | — | US | claimed |
| EP-1140982-A1 | SYNTHESIS AND RECOVERY OF ASPARTAME INVOLVING ENZYMATIC DEFORMYLATION STEP | Holland Sweetener Company V.o.F. (NL) | 2001-10-10 | — | — | EP | claimed |
| WO-2000037486-A1 | SYNTHESIS AND RECOVERY OF ASPARTAME INVOLVING ENZYMATIC DEFORMYLATION STEP | HOLLAND SWEETENER COMPANY V.O.F. (NL) | 2000-06-29 | — | — | WO | claimed |
| EP-1013663-A1 | Synthesis and recovery of aspartame involving enzymatic deformylation step | Holland Sweetener Company V.O.F. (NL) | 2000-06-28 | — | — | EP | claimed |
| CN-113354556-B | C (C)3Chiral ligand H containing symmetrical amide bond3L, preparation method and application | 合肥工业大学 | 2024-07-09 | — | — | CN | disclosed |
| US-12016842-B2 | Methods of using anti-CD79b immunoconjugates | GENENTECH, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240199746-A1 | ANTI-AXL ANTIBODIES, ANTIBODY FRAGMENTS AND THEIR IMMUNOCONJUGATES AND USES THEREOF | BIOATLA, INC. (US) | 2024-06-20 | — | — | US | disclosed |
| EP-3269737-B1 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE | GENENTECH INC (US) | 2024-06-19 | — | — | EP | disclosed |
| EP-4380978-A1 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA | Genentech, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| US-20240115718-A1 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA | GENENTECH, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-20240110909-A1 | BIOANALYTICAL ANALYSIS OF SITE-SPECIFIC ANTIBODY DRUG CONJUGATES | GENENTECH, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-6617127-B2 | Using N-formylaspartylphenylalanine compound | HOLLAND SWEETENER COMPANY, V.O.F. (NL) | 2003-09-09 | — | — | US | disclosed |
| EP-1140982-B1 | SYNTHESIS AND RECOVERY OF ASPARTAME INVOLVING ENZYMATIC DEFORMYLATION STEP | HOLLAND SWEETENER CO (NL) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002048312-A2 | BACKBONE CYCLIZED INHIBITORS OF HEAT SHOCK PROTEINS | PEPTOR LTD. (IL) | 2002-06-20 | — | — | WO | disclosed |
| US-20020025549-A1 | Synthesis and recovery of aspartame involving enzymatic deformylation step | DSM IP ASSETS BV (NL) | 2002-02-28 | — | — | US | disclosed |
| EP-1140982-A1 | SYNTHESIS AND RECOVERY OF ASPARTAME INVOLVING ENZYMATIC DEFORMYLATION STEP | Holland Sweetener Company V.o.F. (NL) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000037486-A1 | SYNTHESIS AND RECOVERY OF ASPARTAME INVOLVING ENZYMATIC DEFORMYLATION STEP | HOLLAND SWEETENER COMPANY V.O.F. (NL) | 2000-06-29 | — | — | WO | disclosed |
| EP-1013663-A1 | Synthesis and recovery of aspartame involving enzymatic deformylation step | Holland Sweetener Company V.O.F. (NL) | 2000-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12016842-B2 | Methods of using anti-CD79b immunoconjugates | CD79B, CD99, BCL6 | SLC7A5 2185/4885ALPI 3962/4885PKM 4789/4885 |
| US-20240110909-A1 | BIOANALYTICAL ANALYSIS OF SITE-SPECIFIC ANTIBODY DRUG CONJUGATES | GUSB, DNPEP, FUCA2 | SLC7A5 1025/4885ALPI 670/4885PKM 4562/4885 |
| US-20240115718-A1 | METHODS OF USING ANTI-CD79B IMMUNOCONJUGATES TO TREAT DIFFUSE LARGE B-CELL LYMPHOMA | CD79B, BCL6, CD99 | SLC7A5 2183/4885ALPI 4619/4885PKM 4372/4885 |
| US-20240199746-A1 | ANTI-AXL ANTIBODIES, ANTIBODY FRAGMENTS AND THEIR IMMUNOCONJUGATES AND USES THEREOF | AXL, CD47, ERBB3 | SLC7A5 4509/4885ALPI 3321/4885PKM 4382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.